Aurum Attending 2018 Bio-Europe Partnering Conference

Aurum Attending 2018 Bio-Europe Partnering Conference

Aurum Biosciences Ltd (, a clinical stage company which has developed an innovative technology that has the potential to save and improve the lives of thousands of people who’ve had a stroke, will be attending the 2018 Bio-Europe Partnership Conference in Copenhagen from the 5th- 7th of November 2018 . CEO Jim McGuire and Executive Chairman Gerry McGettigan will be available to discuss Aurum’s phase 2 stroke trial of its lead product ABL-101 and the companies future plans.

Aurum’s ABL-101 stroke technology is based on an oxygen carrying perflurocarbon (PFC), which is emulsified for intravenous use. This PFC not only acts as a stroke therapeutic, delivering oxygen beyond the stroke clot, but due to its effect on local oxygenation and in combination with MRI imaging, it is able to detect tissue under metabolic stress. Thus, ABL-101 has unique dual benefits of reducing brain cell death following acute stroke, while also providing important information guiding the use of further stroke treatments (Aurum preclinical data in press). Future trials will investigate the effect of ABL-101 on stroke-induced disability both in the overall stroke population, and in thrombectomy patients. The latter is an extremely interesting sub-population of stroke patients in which there have been highly promising recent clinical developments, and which may provide a more rapid route to market for novel stroke therapies.

Further information on Aurum’s ABL-101 technology is discussed in this video.

Stroke is the second biggest killer worldwide with 1 in 6 people having a stroke by the age or 75. Every two seconds someone in the world will have a stroke.  Approximately 15 million worldwide suffer an AIS annually, with the global burden continuing to rise (WHO). However, there is only one authorised medicine to treat acute stroke (alteplase, or rtPA), unlike the dozens of products available to treat other major diseases such as cancer or heart disease.  To date, spending on stroke research and development has been low in the UK, with only £48 spent on research per stroke patient, compared to £241 spent on cancer. [State of Nation -Stroke Statistics 2017] The worldwide acute stroke market was valued at $21.5 billion in 2015 and is forecast to reach $31 billion by 2021 [Zion Research].

Aurum Biosciences Ltd ( is a clinical stage biopharmaceutical company developing novel therapeutics and diagnostics with its lead product having been developed for AIS. Follow-on indications include heart disease, cancer, epilepsy, and dementia. Aurum Biosciences, headed by a team of experts in the field, has already taken the stroke management product ABL-101 through preclinical development and is progressing into the clinic.